Abstract
Abstract
Background
Recommendations for statistical methods in rare disease trials are scarce, especially for cross-over designs. As a result various state-of-the-art methodologies were compared as neutrally as possible using an illustrative data set from epidermolysis bullosa research to build recommendations for count, binary, and ordinal outcome variables. For this purpose, parametric (model averaging), semiparametric (generalized estimating equations type [GEE-like]) and nonparametric (generalized pairwise comparisons [GPC] and a marginal model implemented in the R package nparLD) methods were chosen by an international consortium of statisticians.
Results
It was found that there is no uniformly best method for the aforementioned types of outcome variables, but in particular situations, there are methods that perform better than others. Especially if maximizing power is the primary goal, the prioritized unmatched GPC method was able to achieve particularly good results, besides being appropriate for prioritizing clinically relevant time points. Model averaging led to favorable results in some scenarios especially within the binary outcome setting and, like the GEE-like semiparametric method, also allows for considering period and carry-over effects properly. Inference based on the nonparametric marginal model was able to achieve high power, especially in the ordinal outcome scenario, despite small sample sizes due to separate testing of treatment periods, and is suitable when longitudinal and interaction effects have to be considered.
Conclusion
Overall, a balance has to be found between achieving high power, accounting for cross-over, period, or carry-over effects, and prioritizing clinically relevant time points.
Funder
H2020 Societal Challenges
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Reference36 articles.
1. Aoki Y, Röshammar D, Hamrén B, Hooker AC. Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection. J Pharmacokinet Pharmacodyn. 2017;44(6):581–97. https://doi.org/10.1007/s10928-017-9550-0.
2. Ast (n.d.) ASTERIX: advances in small trials design for regulatory innovation and excellence. FP7-HEALTH-2013-INNOVATION-1 Grant-Agreement No. 603160. https://www.asterix-fp7.eu/
3. Bartlett MS. Properties of sufficiency and statistical tests. Proc R Soc Lond Ser A Math Phys Sci. 1937;160(901):268–82.
4. Brunner E, Bathke AC, Konietschke F. Rank and pseudo-rank procedures for independent observations in factorial designs, using R and SAS. Berlin Heidelberg: Springer; 2019.
5. Brunner E, Munzel U. Nichtparametrische Datenanalyse: Unverbundene Stichproben. Berlin, Heidelberg: Springer; 2013.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Medical Statistics in Drug Development and Regulatory Approval;Advances in Bioinformatics and Biomedical Engineering;2024-07-18